Positive Phase 3 Data for Dupixent in Chronic Spontaneous Urticaria Released

Sanofi-Aventis and Regeneron Pharmaceuticals are set to present promising phase 3 data on Dupixent (dupilumab) for chronic spontaneous urticaria (CSU) at the ACAAI 2024 Annual Scientific Meeting. The study involved 151 patients experiencing uncontrolled CSU despite antihistamine treatment. Results showed a significant reduction in itch and hive activity, with 41% achieving well-controlled disease status. If approved in the US, Dupixent would be the first new targeted treatment for CSU in over a decade.

The LIBERTY-CUPID Study C highlighted improvements with Dupixent regarding itch and urticaria activity scores compared to placebo. Safety results paralleled those seen in its approved dermatological uses. The treatment is already approved for CSU in Japan and the UAE, with regulatory review ongoing in the EU.